CLDX
NASDAQ · Biotechnology
Celldex Therapeutics Inc
$30.90
+0.87 (+2.90%)
Financial Highlights (FY 2026)
Revenue
7.41M
Net Income
-166,653,055
Gross Margin
100.0%
Profit Margin
-2,248.8%
Rev Growth
+14.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 37.0% | 37.0% |
| Operating Margin | -2,778.9% | -2,501.0% | -1.1% | -1.0% |
| Profit Margin | -2,248.8% | -2,136.3% | -0.8% | -1.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 7.41M | 6.46M | 613.37M | 463.47M |
| Gross Profit | 7.41M | 6.46M | 226.87M | 171.43M |
| Operating Income | -205,910,830 | -161,540,923 | -6,648,390 | -4,566,228 |
| Net Income | -166,653,055 | -130,742,459 | -4,777,656 | -4,595,403 |
| Gross Margin | 100.0% | 100.0% | 37.0% | 37.0% |
| Operating Margin | -2,778.9% | -2,501.0% | -1.1% | -1.0% |
| Profit Margin | -2,248.8% | -2,136.3% | -0.8% | -1.0% |
| Rev Growth | +14.7% | +14.7% | +23.6% | +12.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 650.05M | 724.29M |
| Total Equity | — | — | 684.23M | 651.26M |
| D/E Ratio | — | — | 0.95 | 1.11 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -202,587,301 | -167,763,193 | -9,452,277 | -7,129,969 |
| Free Cash Flow | — | — | -4,482,621 | -2,547,498 |